Open AccessMost Clinical Studies Do Not Report FDA Recommendations For Endpoints In NAFLD/NASH
Author(s) -
Debora de Melo Behrens,
Stella L. Volpe,
Vagner Raso
Publication year - 2021
Publication title -
medicine and science in sports and exercise
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.703
H-Index - 224
eISSN - 1530-0315
pISSN - 0195-9131
DOI - 10.1249/01.mss.0000764484.54799.31
Subject(s) - steatohepatitis , medicine , fatty liver , liraglutide , clinical trial , placebo , pioglitazone , clinical endpoint , liver disease , gastroenterology , disease , physical therapy , diabetes mellitus , type 2 diabetes , pathology , alternative medicine , endocrinology